STERIS plc (STE)

Nov 4, 2026

Shares of AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS rose after election results confirmed Democrats reclaimed majorities in Congress, easing regulatory uncertainty in the biopharmaceutical sector. Wall Street analysts expect a strengthened recovery for the sector as drug pricing legislation is deemed unlikely to dominate the new legislative agenda. Broader equity markets also rebounded, viewing congressional checks and balances as a stabilizing force for policy decisions and investments.

Oct 30, 2026

Shares of Steris PLC (STE) fell 2.16% to $227.12 on Friday, contrasting with a broader market decline where the S&P 500 Index and Dow Jones Industrial Average also dropped. This decline ended a two-day winning streak for the stock.

Oct 30, 2026

Soltis Investment Advisors LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 26.5%, purchasing an additional 35,100 shares to bring its total holdings to 167,746 shares valued at approximately $14.5 million. This acquisition highlights institutional confidence, despite recent insider sales totaling nearly $5.9 million. Medtronic reported strong quarterly earnings, exceeding analyst expectations, and offers a 3.0% annual dividend yield.

Oct 29, 2026

Shares of Steris PLC (STE) rose 1.47% to $232.14 on Thursday, outperforming the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marks the second consecutive day of gains for the company's stock.

Oct 29, 2026

STERIS plc (NYSE:STE) has declared a quarterly dividend of $0.69 per share, maintaining its 20-year streak of dividend increases. The dividend is payable on December 17th to shareholders of record on November 17th, representing an annualized dividend of $2.76 and a yield of 1.2%. The company's dividend payout ratio of 25.1% indicates strong coverage by earnings, with analysts projecting continued coverage based on future EPS estimates.

Oct 28, 2026

STERIS (NYSE:STE) is anticipated to report its Q2 fiscal 2027 earnings on Wednesday, November 4th, with analysts forecasting EPS of $2.67 and revenue of $1.56 billion. The company's previous quarter exceeded expectations, reporting EPS of $2.59, beating the consensus of $2.49, and saw a 7.3% year-over-year revenue increase. STERIS also recently raised its quarterly dividend to $0.69, and analysts maintain a "Moderate Buy" rating with an average price target of $271.33.

Oct 27, 2026

Cooper Companies announced that CEO Al White has stepped down, effective immediately, with board member Walt Rosebrough elected as executive chair while the company searches for a new CEO. This leadership change comes amid recent performance not meeting expectations and follows involvement from activist investors. The company also reaffirmed its fiscal 2026 forecast.

Oct 27, 2026

Aptar Pharma and Stevanato Group have announced a collaboration to provide system-level data that supports earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies. This joint effort will focus on sensitive biologics and other injectable therapies, helping drug manufacturers make more informed decisions and identify potential technical challenges sooner in the development process. The initiative builds on Aptar Pharma's integrated system-level framework launched in July 2026, combining their expertise in elastomeric components with Stevanato Group's knowledge in pre-fillable syringe systems.

Oct 27, 2026

Deroy & Devereaux Private Investment Counsel Inc. increased its stake in STERIS plc (NYSE:STE) by 51.0% during the third quarter, acquiring an additional 8,560 shares to bring its total holdings to 25,355 shares valued at $5.3 million. Other institutional investors have also adjusted their positions in STERIS, which is favorably rated by analysts with a "Moderate Buy" consensus and an average price target of $271.33. STERIS reported strong quarterly earnings, beating EPS estimates and increasing revenue by 7.3% year-over-year, alongside a boost in its quarterly dividend to $0.69 per share.